Sathy V. Balu-Iyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sathy V. Balu-Iyer has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Gautam N. Shenoy
Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA
22 shared publications Raymond J. Kelleher
22 shared publicationsJenni Loyall
21 shared publications- Kunle Odunsi
University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA
21 shared publications - Paul K. Wallace
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK
21 shared publications - Richard B. Bankert
Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA
21 shared publications
Latest Publications
- 7 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- p. 104527
Immunogenicity of biologics delivered in the subcutaneous space: Delineating the contributing factors
- 7 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- p. 104527
Immunogenicity of biologics delivered in the subcutaneous space: Delineating the contributing factors
- Open Access
Lysophosphatidylserine Nanoparticles Induce Oral Tolerance Independent of TIM-4 and Canonical PS Processing
Protein replacement therapy is highly effective for treating many protein-deficiency disorders, but its long-term clinical benefit is often limited by anti-drug antibody responses that neutralize therapeutic proteins, compromising safety and efficacy. To address these unwanted immune responses, a lipid nanoparticle–based immunotherapy platform has been developed to induce antigen-specific tolerance. Mice treated with antigen associated with either double-chain phosphatidylserine (PS) or lysophosphatidylserine (LysoPS), a single-acyl-chain phospholipid, showed reduced antibody titers following subcutaneous pre-exposure. However, only LysoPS nanoparticles induced tolerance after oral administration, suggesting structural differences between PS and LysoPS can impact tolerogenic potential, depending on the site of delivery. As an apoptotic “eat-me” signal, PS is recognized by phagocytic receptors such as TIM-4 and is associated with LC3-associated phagocytosis. These nanoparticles have been hypothesized to promote “apoptotic mimicry” to regulate immunity. However, the contribution of TIM-4 to oral tolerance remains unclear. Here, we investigated the role of TIM-4 in LysoPS-mediated oral tolerance using a knockout mouse model. Our data showed that TIM-4 -/- mice induced tolerance to ovalbumin encapsulated in LysoPS comparable to that of wild-type mice. We also found that LysoPS nanoparticles did not follow the same surface engagement and intracellular trafficking pathways as PS nanoparticles. These results reveal that, despite sharing the same headgroup, differences in acyl chain number critically shape nanoparticle–immune cell interactions and provide a mechanistic framework that may explain the unique ability of LysoPS nanoparticles to induce oral tolerance.
Open AccessLysophosphatidylserine Nanoparticles Induce Oral Tolerance Independent of TIM-4 and Canonical PS Processing
Protein replacement therapy is highly effective for treating many protein-deficiency disorders, but its long-term clinical benefit is often limited by anti-drug antibody responses that neutralize therapeutic proteins, compromising safety and efficacy. To address these unwanted immune responses, a lipid nanoparticle–based immunotherapy platform has been developed to induce antigen-specific tolerance. Mice treated with antigen associated with either double-chain phosphatidylserine (PS) or lysophosphatidylserine (LysoPS), a single-acyl-chain phospholipid, showed reduced antibody titers following subcutaneous pre-exposure. However, only LysoPS nanoparticles induced tolerance after oral administration, suggesting structural differences between PS and LysoPS can impact tolerogenic potential, depending on the site of delivery. As an apoptotic “eat-me” signal, PS is recognized by phagocytic receptors such as TIM-4 and is associated with LC3-associated phagocytosis. These nanoparticles have been hypothesized to promote “apoptotic mimicry” to regulate immunity. However, the contribution of TIM-4 to oral tolerance remains unclear. Here, we investigated the role of TIM-4 in LysoPS-mediated oral tolerance using a knockout mouse model. Our data showed that TIM-4 -/- mice induced tolerance to ovalbumin encapsulated in LysoPS comparable to that of wild-type mice. We also found that LysoPS nanoparticles did not follow the same surface engagement and intracellular trafficking pathways as PS nanoparticles. These results reveal that, despite sharing the same headgroup, differences in acyl chain number critically shape nanoparticle–immune cell interactions and provide a mechanistic framework that may explain the unique ability of LysoPS nanoparticles to induce oral tolerance.
- 5 July 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (9) , 104404
Immune tolerance platforms to mitigate unwanted immune responses
- 5 July 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (9) , 104404
Immune tolerance platforms to mitigate unwanted immune responses
- 24 April 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (6) , 104297
First step towards predicting clinical immunogenicity of biologics using in vitro based readouts as animal trial alternatives
- 24 April 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (6) , 104297
First step towards predicting clinical immunogenicity of biologics using in vitro based readouts as animal trial alternatives
- Open Access
- 29 March 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (7) , 412
Intestinal Microfold Cells Play a Critical Role in the Uptake and Oral Tolerance Mediated by Lysophosphatidylserine-Containing Lipidic Nanoparticles
Phosphatidylserine (PS) is an anionic phospholipid that is exposed to the outer leaflet of the cell membrane during apoptosis. This PS externalization can teach the immune system to tolerate an antigen without eliciting immunological consequences. Previously, we showed that mice treated with PS nanoparticles containing single-chain PS (LysoPS) induced oral tolerance towards therapeutic proteins, whereas double-chain PS did not. These observations suggest that structural alterations of PS play a critical role in its tolerogenic potential. Given that intestinal microfold cells (M-cells) facilitate the transport of particulate antigens from the intestinal lumen to Peyer’s patches (PP) for immune surveillance, we hypothesized that the failure of double-chain PS to induce tolerance may result from insufficient uptake by M-cells. The M cell-mediated uptake was investigated using in vitro and ex vivo studies and oral tolerance towards ovalbumin (OVA) was studied in M-cell-deficient mice. Consistent with this hypothesis, our data showed that LysoPS nanoparticles displayed at least a 2-fold increase in immune cell exposure and M-cell-mediated uptake compared to double-chain PS-containing nanoparticles. Importantly, LysoPS-mediated oral tolerance was absent in M cell-deficient mice with higher anti-ova antibody titers than the wild-type strain. These studies demonstrate that higher PS exposure on LysosPS nanoparticles compared to double chain could play a significant role in M cell-mediated tolerance.
- 29 March 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (7) , 412
Open AccessIntestinal Microfold Cells Play a Critical Role in the Uptake and Oral Tolerance Mediated by Lysophosphatidylserine-Containing Lipidic Nanoparticles
Phosphatidylserine (PS) is an anionic phospholipid that is exposed to the outer leaflet of the cell membrane during apoptosis. This PS externalization can teach the immune system to tolerate an antigen without eliciting immunological consequences. Previously, we showed that mice treated with PS nanoparticles containing single-chain PS (LysoPS) induced oral tolerance towards therapeutic proteins, whereas double-chain PS did not. These observations suggest that structural alterations of PS play a critical role in its tolerogenic potential. Given that intestinal microfold cells (M-cells) facilitate the transport of particulate antigens from the intestinal lumen to Peyer’s patches (PP) for immune surveillance, we hypothesized that the failure of double-chain PS to induce tolerance may result from insufficient uptake by M-cells. The M cell-mediated uptake was investigated using in vitro and ex vivo studies and oral tolerance towards ovalbumin (OVA) was studied in M-cell-deficient mice. Consistent with this hypothesis, our data showed that LysoPS nanoparticles displayed at least a 2-fold increase in immune cell exposure and M-cell-mediated uptake compared to double-chain PS-containing nanoparticles. Importantly, LysoPS-mediated oral tolerance was absent in M cell-deficient mice with higher anti-ova antibody titers than the wild-type strain. These studies demonstrate that higher PS exposure on LysosPS nanoparticles compared to double chain could play a significant role in M cell-mediated tolerance.
- Open Access
- 10 January 2026
- Published by Springer Nature in BioDrugs
- Vol. 40 (2) , 215-236
Immunogenicity of Gene and Cell Therapies
Gene and cell therapies have been gaining popularity with market approvals by the US Food and Drug Administration, European Medicines Agency, and other regulatory bodies. Adeno-associated viral vector gene therapies approved for rare inherited diseases and chimeric antigen receptor T-cell therapies approved as a novel modality for hematological anti-cancer therapies have led the way in a new paradigm of drug discovery and development. Previously incurable diseases such as hemophilia A and B have now been effectively treated via adeno-associated viral vector-mediated gene therapy, and chimeric antigen receptor T-cell therapies have provided cures for lymphomas in patients refractory to all previous treatments demonstrating the great promise of these agents. Immunogenicity is a major factor hampering the efficacy and eligible population of gene therapies as well as creates a safety risk for some individuals. Inherent attributes of adeno-associated viral vector gene and autologous chimeric antigen receptor T-cell therapies present a unique set of factors that can influence immunogenicity to the drug compared to widely used small-molecule or biologic drugs. This review outlines immunogenicity concerns of gene and cell therapy, and their clinical manifestations. We detail mechanisms by which these therapies can trigger innate, humoral, and cellular immunity. Additionally, we give an in-depth discussion of in silico, in vitro, and in vivo immunogenicity screening methods that have been applied in gene and cell therapy development, and the utility of each.
- 10 January 2026
- Published by Springer Nature in BioDrugs
- Vol. 40 (2) , 215-236
Open AccessImmunogenicity of Gene and Cell Therapies
Gene and cell therapies have been gaining popularity with market approvals by the US Food and Drug Administration, European Medicines Agency, and other regulatory bodies. Adeno-associated viral vector gene therapies approved for rare inherited diseases and chimeric antigen receptor T-cell therapies approved as a novel modality for hematological anti-cancer therapies have led the way in a new paradigm of drug discovery and development. Previously incurable diseases such as hemophilia A and B have now been effectively treated via adeno-associated viral vector-mediated gene therapy, and chimeric antigen receptor T-cell therapies have provided cures for lymphomas in patients refractory to all previous treatments demonstrating the great promise of these agents. Immunogenicity is a major factor hampering the efficacy and eligible population of gene therapies as well as creates a safety risk for some individuals. Inherent attributes of adeno-associated viral vector gene and autologous chimeric antigen receptor T-cell therapies present a unique set of factors that can influence immunogenicity to the drug compared to widely used small-molecule or biologic drugs. This review outlines immunogenicity concerns of gene and cell therapy, and their clinical manifestations. We detail mechanisms by which these therapies can trigger innate, humoral, and cellular immunity. Additionally, we give an in-depth discussion of in silico, in vitro, and in vivo immunogenicity screening methods that have been applied in gene and cell therapy development, and the utility of each.
- Open Access
- 13 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Phosphatidylserine exposure on tolerogenic nanoparticle correlate with oral tolerance
Unwanted immune responses against therapeutic proteins compromise treatment safety and therapeutic efficacy in patients. To mitigate these immune responses, we developed phosphatidylserine (PS)-containing lipid nanoparticles that mimic the surface properties of apoptotic cells, thereby converting an immunogen into a tolerogen. Previous studies have shown that mice prophylactically treated with PS nanoparticles- either double-chain PS or single-chain PS (LysoPS), administered intravenously or subcutaneously, suppressed humoral immune responses against therapeutic proteins such as Factor VIII (FVIII) and α-Glucosidase (GAA). However, only LysoPS successfully induced oral tolerance, whereas double-chain PS did not. This suggests that the structure of PS alters immune responses when given orally. To understand the structure of PS on the impacts on oral tolerance, we formulated dimyristoyl phosphatidylcholine (DMPC) nanoparticles containing PS variants that differed in the number of acyl chains, degree of unsaturation, and carbon chain length. These structural modifications affected PS surface exposure on the nanoparticles, which in turn modulated their tolerogenic potential. Using ovalbumin (OVA) as a model antigen, we evaluated immune responses in the presence or absence of different PS nanoparticles. Our data revealed that PS structure significantly influenced its surface exposure, which inversely correlated with OVA-specific IgG1 antibody titers and directly correlated with the frequency of T helper 3 cells (Th3). These findings highlight a structure–function relationship in PS-mediated oral tolerance, demonstrating that specific PS configurations can enhance tolerogenic outcomes by increasing PS surface exposure. This insight supports the rational design of PS-based oral immunotherapies to treat clinical conditions involving unwanted immune responses.
- 13 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPhosphatidylserine exposure on tolerogenic nanoparticle correlate with oral tolerance
Unwanted immune responses against therapeutic proteins compromise treatment safety and therapeutic efficacy in patients. To mitigate these immune responses, we developed phosphatidylserine (PS)-containing lipid nanoparticles that mimic the surface properties of apoptotic cells, thereby converting an immunogen into a tolerogen. Previous studies have shown that mice prophylactically treated with PS nanoparticles- either double-chain PS or single-chain PS (LysoPS), administered intravenously or subcutaneously, suppressed humoral immune responses against therapeutic proteins such as Factor VIII (FVIII) and α-Glucosidase (GAA). However, only LysoPS successfully induced oral tolerance, whereas double-chain PS did not. This suggests that the structure of PS alters immune responses when given orally. To understand the structure of PS on the impacts on oral tolerance, we formulated dimyristoyl phosphatidylcholine (DMPC) nanoparticles containing PS variants that differed in the number of acyl chains, degree of unsaturation, and carbon chain length. These structural modifications affected PS surface exposure on the nanoparticles, which in turn modulated their tolerogenic potential. Using ovalbumin (OVA) as a model antigen, we evaluated immune responses in the presence or absence of different PS nanoparticles. Our data revealed that PS structure significantly influenced its surface exposure, which inversely correlated with OVA-specific IgG1 antibody titers and directly correlated with the frequency of T helper 3 cells (Th3). These findings highlight a structure–function relationship in PS-mediated oral tolerance, demonstrating that specific PS configurations can enhance tolerogenic outcomes by increasing PS surface exposure. This insight supports the rational design of PS-based oral immunotherapies to treat clinical conditions involving unwanted immune responses.
- Open Access
- 18 August 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (10) , 103964
Increased longevity of circulating human IgG in an NSG Fc gamma receptor-1 deficient humanized mouse model
- 18 August 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (10) , 103964
Open AccessIncreased longevity of circulating human IgG in an NSG Fc gamma receptor-1 deficient humanized mouse model
- 8 June 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (11) , 103870
Immunogenicity risk mitigation of therapeutic proteins with translational immunogenicity, analytical characterization, and regulatory insight
- 8 June 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (11) , 103870
Immunogenicity risk mitigation of therapeutic proteins with translational immunogenicity, analytical characterization, and regulatory insight